Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

57.00
-0.4800-0.84%
Post-market: 57.490.4900+0.86%19:59 EDT
Volume:10.13M
Turnover:580.70M
Market Cap:116.04B
PE:16.47
High:58.25
Open:58.22
Low:57.00
Close:57.48
52wk High:62.89
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.44
T/O Rate:0.50%
Dividend:2.49
Dividend Rate:4.37%
EPS(TTM):3.46
EPS(LYR):3.46
ROE:40.44%
ROA:10.29%
PB:6.28
PE(LYR):16.47

Loading ...

Bristol Myers Q4 Adj EPS Includes Net Impact of $-0.60 Due to Acquired Iprd Charges & Licensing Income

THOMSON REUTERS
·
Feb 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 05

U.S. Earnings Preview: Before Market Open Feb. 5

Dow Jones
·
Feb 05

Shanghai Pharmaceutical to Transfer Sino-American Shanghai Squibb Pharmaceutical for Not Less Than 1.02 Billion Yuan

MT Newswires Live
·
Feb 05

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 05

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Feb 05

What's Going On With Bristol-Myers Squibb Stock Today?

Benzinga_recent_news
·
Feb 05

Bristol Myers Squibb Expected to Report Lower 4Q Revenue -- Earnings Preview

Dow Jones
·
Feb 05

Shanghai Pharma Plans Full Divestiture of Stake in Sino-American Shanghai Squibb

Deep News
·
Feb 04

Bristol Myers Squibb Teams up With Kasey Keller to Share His Lymphoma Journey With Breyanzi

THOMSON REUTERS
·
Feb 04

Shanghai Pharmaceuticals Holding to Divest 30% Stake in Sino-American Shanghai Squibb Through Public Listing

Stock News
·
Feb 04

BRIEF-Oxford BioMedica Signs Multi-Year Supply Agreement With Bristol Myers Squibb

Reuters
·
Feb 04

Oxford Biomedica Plc - Signs Multi-Year Supply Agreement With Bristol Myers Squibb

THOMSON REUTERS
·
Feb 04

Oxford Biomedica Plc: Multi-Year Agreement With Five-Year Initial Term and Option to Extend

THOMSON REUTERS
·
Feb 04

Oxford Biomedica Plc: Under New Agreement, Oxb Is Expected to Commence Commercial Manufacturing in 2026

THOMSON REUTERS
·
Feb 04

Health Rounds: Cancer immunotherapies may be more effective given earlier in the day

Reuters
·
Feb 04

BRIEF-Bristol Myers Squibb Launches Campaign With Johnson & Johnson

Reuters
·
Feb 03

BRIEF-Opdivo Plus Yervoy Reimbursed Under Ontario's Fast Program As First-Line Treatment For Advanced Liver Cancer

Reuters
·
Feb 03

Opdivo® Plus Yervoy® Reimbursed Under Ontario's Fast Program as First-Line Treatment for Advanced Liver Cancer

THOMSON REUTERS
·
Feb 03

Bristol Myers Squibb startet Zusammenarbeit mit Johnson & Johnson zur Entwicklung neuer Thrombose-Therapien

Reuters
·
Feb 03